

**12 December 2022**

## **ASX Announcement**

### **Island investor briefing invitation**

MELBOURNE Australia, 12 December 2022: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; “Island”; “the Company”) is pleased to invite investors to attend a special online briefing on Thursday 15 December 2022 at 10:30am AEDT (Melbourne time).

Island’s CEO and Managing Director, Dr David Foster commented, *“We have been working diligently toward the commencement of our ISLA-101 Phase 2a clinical trial in dengue fever and are moving quickly toward the achievement of a number of important milestones. Through this online briefing, we will discuss those coming activities in detail and provide an update on how the the final stages of our clinical trial preparation are coming together.”*

#### Registration info

The online briefing will be held on Thursday, 15 December at 10:30am Melbourne time (AEDT). The session will include a presentation by Dr Foster, followed by a Q&A session.

Investors are invited to register ahead of time, via the following link:  
[https://us02web.zoom.us/webinar/register/WN\\_vLoT\\_dTvQgOz4I5pqy2YJg](https://us02web.zoom.us/webinar/register/WN_vLoT_dTvQgOz4I5pqy2YJg)

Once the registration form is completed, participants will receive a confirmation email with detail on how to access the briefing.

Island looks forward to welcoming those investors able to join the session, and will make a recorded copy available in the week after the event.

#### **Approved for release to the ASX by:**

Dr Paul MacLeman  
Executive Chairman  
Island Pharmaceuticals Ltd  
[info@islandpharmaceuticals.com](mailto:info@islandpharmaceuticals.com)

Investors and media, for further information, please contact:

Jane Lowe  
IR Department  
Mobile: +61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)



## About Island Pharmaceuticals

---

Island (ASX: ILA) is a mid-clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue<sup>2</sup> fever and other mosquito (or vector) borne diseases. The Company is close to commencing a Phase 2a clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

*Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.*

Visit [www.islandpharmaceuticals.com](http://www.islandpharmaceuticals.com) for more on Island.